, Columnist
Allergan Is Making Biotech Expensive Again
It's throwing mountains of cash at targets, lifting the whole sector.
This article is for subscribers only.
Allergan seems to be trying to revive biotech single-handedly.
Less than a week after announcing a deal at a 159 percent premium for dermatology drugmaker Vitae, Allergan revealed on Tuesday it is paying an even bigger mark-up for Tobira Therapeutics and its drug candidate for non-alcoholic steatohepatitis (NASH), a liver disease.